ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Mechanisms and clinical research progress of mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease].
Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation. The efficacy of standard first-line glucocorticoid treatment is limited; more than 40% of patients develop steroid-refractory aGVHD with an extremely poor prognosis. In recent years, mesenchymal stromal cell (MSC) as a second-line treatment for steroid-refractory aGVHD has been widely studied worldwide. In 2025, the first domestic MSC product was conditional approved by the National Medical Products Administration for steroid-refractory aGVHD in patients aged 14 years and above in China. In light of this, this article reviews the clinical research progress of MSC in the treatment of steroid-refractory aGVHD, focusing on mechanisms and efficacy evaluation, aiming to deepen the understanding of the clinical potential and existing challenges of MSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.